Logo image of AUTL

AUTOLUS THERAPEUTICS PLC (AUTL) Stock Price, Quote, News and Overview

NASDAQ:AUTL - Nasdaq - US05280R1005 - ADR - Currency: USD

1.95  0 (0%)

After market: 1.9599 +0.01 (+0.51%)

AUTL Quote, Performance and Key Statistics

AUTOLUS THERAPEUTICS PLC

NASDAQ:AUTL (2/21/2025, 8:02:17 PM)

After market: 1.9599 +0.01 (+0.51%)

1.95

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High6.63
52 Week Low1.87
Market Cap518.94M
Shares266.12M
Float213.36M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO06-22 2018-06-22


AUTL short term performance overview.The bars show the price performance of AUTL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40 -50

AUTL long term performance overview.The bars show the price performance of AUTL in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60

The current stock price of AUTL is 1.95 USD. In the past month the price decreased by -14.85%. In the past year, price decreased by -68.09%.

AUTOLUS THERAPEUTICS PLC / AUTL Daily stock chart

AUTL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About AUTL

Company Profile

AUTL logo image Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The company is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. The company has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Company Info

AUTOLUS THERAPEUTICS PLC

The Mediaworks, 191 Wood Lane

London W12 7RZ GB

CEO: Christian Itin

Employees: 467

Company Website: https://www.autolus.com/

Investor Relations: https://www.autolus.com/investor-relations/

Phone: 442038296230

AUTOLUS THERAPEUTICS PLC / AUTL FAQ

What is the stock price of AUTOLUS THERAPEUTICS PLC today?

The current stock price of AUTL is 1.95 USD.


What is the ticker symbol for AUTOLUS THERAPEUTICS PLC stock?

The exchange symbol of AUTOLUS THERAPEUTICS PLC is AUTL and it is listed on the Nasdaq exchange.


On which exchange is AUTL stock listed?

AUTL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AUTOLUS THERAPEUTICS PLC stock?

17 analysts have analysed AUTL and the average price target is 10.38 USD. This implies a price increase of 432.38% is expected in the next year compared to the current price of 1.95. Check the AUTOLUS THERAPEUTICS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AUTOLUS THERAPEUTICS PLC worth?

AUTOLUS THERAPEUTICS PLC (AUTL) has a market capitalization of 518.94M USD. This makes AUTL a Small Cap stock.


How many employees does AUTOLUS THERAPEUTICS PLC have?

AUTOLUS THERAPEUTICS PLC (AUTL) currently has 467 employees.


What are the support and resistance levels for AUTOLUS THERAPEUTICS PLC (AUTL) stock?

AUTOLUS THERAPEUTICS PLC (AUTL) has a support level at 1.94 and a resistance level at 2.05. Check the full technical report for a detailed analysis of AUTL support and resistance levels.


Is AUTOLUS THERAPEUTICS PLC (AUTL) expected to grow?

The Revenue of AUTOLUS THERAPEUTICS PLC (AUTL) is expected to grow by 487.76% in the next year. Check the estimates tab for more information on the AUTL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AUTOLUS THERAPEUTICS PLC (AUTL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AUTOLUS THERAPEUTICS PLC (AUTL) stock pay dividends?

AUTL does not pay a dividend.


What is the Price/Earnings (PE) ratio of AUTOLUS THERAPEUTICS PLC (AUTL)?

AUTOLUS THERAPEUTICS PLC (AUTL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.22).


What is the Short Interest ratio of AUTOLUS THERAPEUTICS PLC (AUTL) stock?

The outstanding short interest for AUTOLUS THERAPEUTICS PLC (AUTL) is 4.27% of its float. Check the ownership tab for more information on the AUTL short interest.


AUTL Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

AUTL Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AUTL. The financial health of AUTL is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AUTL Financial Highlights

Over the last trailing twelve months AUTL reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS decreased by -24.49% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -25.18%
ROE -43.69%
Debt/Equity 0.52
Chartmill High Growth Momentum
EPS Q2Q%-19.23%
Sales Q2Q%-100%
EPS 1Y (TTM)-24.49%
Revenue 1Y (TTM)-73.3%

AUTL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to AUTL. The Buy consensus is the average rating of analysts ratings from 17 analysts.

For the next year, analysts expect an EPS growth of 22.01% and a revenue growth 487.76% for AUTL


Ownership
Inst Owners83.99%
Ins Owners0.01%
Short Float %4.27%
Short Ratio6.42
Analysts
Analysts85.88
Price Target10.38 (432.31%)
EPS Next Y22.01%
Revenue Next Year487.76%